

FOR IMMEDIATE RELEASE

AMERICAN VANGUARD REPORTS THIRD QUARTER AND NINE-MONTH 2022 RESULTS

YTD Revenues and Adjusted EBITDA¹ Exceed Guidance Forecasting Continued Strategic Growth

Newport Beach, CA – November 8, 2022 – American Vanguard Corporation (NYSE: AVD), today announced financial results for the third quarter and nine months ended September 30, 2022.

Financial Highlights Fiscal 2022 Third Quarter – versus Fiscal 2021 Third Quarter

- Net sales of \$152 million in 2022, a 3.4% increase, compared with \$147 million in 2021
- Net income of \$6.7 million in 2022, a 21.8% increase, compared with \$5.5 million in 2021
- Earnings per diluted share of \$0.23 in 2022, a 27.8% increase, compared with \$0.18 in 2021
- Adjusted EBITDA of \$18.9 million in 2022, a 11.2% increase, compared with \$17.0 million in 2021

Financial Highlights Fiscal 2022 Nine Months – versus Fiscal 2021 Nine Months

- Net sales of \$450 million in 2022, a 13.1% increase, compared with \$398 million in 2021
- Net income of \$23.5 million in 2022, a 71.5% increase, compared with \$13.7 million in 2021
- Earnings per diluted share of \$0.78 in 2022, a 73.3% increase, compared with \$0.45 in 2021
- Adjusted EBITDA of \$61.4 million in 2022, a 29.8% increase, compared to \$47.3 million in 2021

Eric Wintemute, Chairman and CEO of American Vanguard commented, "We achieved strong third quarter results and through the first nine months of 2022 and are on pace to meet or exceed our full year performance targets. High crop commodity prices, a strong farm economy and seasonal pest pressure (particularly in corn and cotton) fueled continued growth of our US Crop business. Similarly, our international business recorded strong sales, led by Brazil (particularly our Counter nematicide), Mexico (due largely to soil fumigant sales) and a range of products for use on bananas and pineapples in Central America. Partially offsetting these

¹ Adjusted earnings before interest, taxes, depreciation, amortization, non-cash stock compensation, and proxy contest activities. Adjusted EBITDA is not a financial measure calculated and presented in accordance with U.S. generally accepted accounting principles (GAAP) and should not be considered as an alternative to net income (loss), operating income (loss) or any other financial measure so calculated and presented, nor as an alternative to cash flow from operating activities as a measure of liquidity. The items excluded from Adjusted EBITDA are detailed in the reconciliation attached to this news release. Other companies (including the Company's competitors) may define Adjusted EBITDA differently.

gains, we experienced a decrease in net sales of our domestic non-crop business, due largely to softening of consumer spending in the lawn and garden markets."

Mr. Wintemute continued, "Our year-to-date revenue performance exceeds the full-year 2022 growth target for net sales that we had set last March (13% actual growth v. 8-11% target), as does net income (71% actual growth v. 60-70% target) and adjusted EBITDA (30% actual growth v. 24-28% target). Faced with inflationary cost increases, supply chain challenges and high demand, we were able to implement appropriate price increases while maximizing factory activity. These factors contributed to higher net income as a percent of net sales for both the quarter and the first nine months. Additionally, we expect significant year-end debt reduction and a full-year adjusted EBITDA of approximately \$80 million or 13% of expected sales. Finally, through a combination of an Accelerated Share Repurchase Plan and a 10b5-1 purchase plan, we acquired 1.5 million shares of AVD common stock during the first nine months of the year. These repurchases demonstrate our belief in the company's long-term value and serve to enhance shareholder investment."

Mr. Wintemute concluded, "We continue to pursue strategic growth initiatives to expand our core business and develop new technologies, with particular emphasis on Green Solutions and Precision Application innovations. As we announced over the past few weeks, we have established an alliance with NewLeaf Symbiotics, which will complement our existing portfolio of patented biological plant nutrients and soil health enrichments. In addition, we secured registration approval for use of our Counter nematicide on soybeans in Brazil, which will improve market penetration with a proprietary product, while advancing the adoption of SIMPAS prescription application technology in the largest Agricultural market in the world. We look forward to providing details on current business trends and these growth initiatives in our upcoming quarterly conference call."

Conference Call

Eric Wintemute, Chairman & CEO, Bob Trogele EVP & COO and David T. Johnson, VP & CFO, will conduct a conference call focusing on the financial results at 4:30 pm ET / 1:30 pm PT on Monday, November 8, 2022. Interested parties may participate in the call by dialing 201-493-6744 – please dial in 10 minutes before the call is scheduled to begin and ask for the American Vanguard call. The conference call will also be webcast live via the News and Media section of the Company's web site at www.american-vanguard.com. To listen to the live webcast, go to the web site at least 15 minutes early to register, download and install any necessary audio software. If you are unable to listen live, the conference call will be archived on the Company's web site.

About American Vanguard

American Vanguard Corporation is a diversified specialty and agricultural products company that develops and markets products for crop protection and management, turf and ornamentals management and public and animal health. American Vanguard is included on the Russell 2000® and Russell 3000® Indexes and the Standard & Poor's Small Cap 600 Index. To learn more about American Vanguard, please reference the Company's web site at www.american-vanguard.com.

The Company, from time to time, may discuss forward-looking information. Except for the historical information contained in this release, all forward-looking statements are estimates by the Company's management and are subject to various risks and uncertainties that may cause results to differ from management's current expectations. Such factors include weather conditions, changes in regulatory policy and other risks as detailed from time-to-time in the Company's SEC reports and filings. All forward-looking statements, if any, in this release represent the Company's judgment as of the date of this release.

Company Contact:

American Vanguard Corporation William A. Kuser, Director of Investor Relations (949) 260-1200 williamk@amvac.com

Investor Representative

The Equity Group Inc. www.theequitygroup.com Lena Cati (212) 836-9611 Lcati@equityny.com

AMERICAN VANGUARD CORPORATION AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except share data)

(Unaudited)

ASSETS	Sep	otember 30, 2022	December 31, 2021		
Current assets:					
Cash and cash equivalents	\$	20,808	\$	16,285	
Receivables:					
Trade, net of allowance for doubtful accounts of \$4,535 and \$3,938,					
respectively		194,515		149,326	
Other		10,022		9,595	
Total receivables, net		204,537		158,921	
Inventories		192,309		154,306	
Prepaid expenses		16,967		12,488	
Income taxes receivable		2,180		<u> </u>	
Total current assets		436,801		342,000	
Property, plant and equipment, net		68,598		66,111	
Operating lease right-of-use assets		25,402		25,386	
Intangible assets, net		187,207		197,841	
Goodwill		46,215		46,260	
Other assets		11,936		16,292	
Deferred income tax assets, net		16		270	
Total assets	\$	776,175	\$	694,160	
LIABILITIES AND STOCKHOLDERS' EQUI	ΓV				
Current liabilities:					
Current installments of other liabilities	\$	_	\$	802	
Accounts payable	-	81,919	-	67,140	
Customer prepayments		222		63,064	
Accrued program costs		108,016		63,245	
Accrued expenses and other payables		24,390		20,745	
Income taxes payable				3,006	
Current operating lease liabilities		5,329		5,059	
Total current liabilities		219,876		223,061	
Long-term debt, net		148,414		52,240	
Long-term operating lease liabilities		20,536		20,780	
Other liabilities, net of current installments		5,457		5,335	
Deferred income tax liabilities, net		19,324		20,006	
Total liabilities		413,607		321,422	
Commitments and contingent liabilities		<u> </u>			
Stockholders' equity:					
Preferred stock, \$.10 par value per share; authorized 400,000 shares; none issued		_		_	
Common stock, \$.10 par value per share; authorized 40,000,000 shares; issued 34,463,947 shares at September 30, 2022 and 34,248,218 shares at December 31,					
2021		3,446		3,426	
Additional paid-in capital		101,426		101,450	
Accumulated other comprehensive loss		(15,532)		(13,784)	
Retained earnings		325,698		304,385	
Less treasury stock at cost, 4,884,200 shares at September 30, 2022 and 3,361,040		222,070		201,303	
shares at December 31, 2021		(52,470)		(22,739)	
Total stockholders' equity		362,568		372,738	
Total liabilities and stockholders' equity	\$	776,175	\$	694,160	
and decommended by	<u> </u>	,173	<u> </u>	0, 1,100	

AMERICAN VANGUARD CORPORATION AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share data) (Unaudited)

	For the Three Months Ended September 30,			F	For the Nine Months En September 30,			
	2022 2021				2022		2021	
Net sales	\$ 152,117	\$	147,298	\$	449,636	\$	398,063	
Cost of sales	(90,733)		(90,234)		(267,280)		(243,729)	
Gross profit	61,384		57,064		182,356		154,334	
Operating expenses	(50,140)		(48,410)		(145,550)		(132,934)	
Adjustment to bargain purchase gain on business acquisition	_		292		_		171	
Operating income	11,244		8,946		36,806		21,571	
Change in fair value of equity investments	(454)		(668)		(857)		103	
Other income	_		_		_		672	
Interest expense, net	(1,086)		(962)		(2,256)		(2,921)	
Income before provision for income taxes and loss on equity								
method investment	9,704		7,316		33,693		19,425	
Income tax expense	(2,963)		(1,517)		(10,187)		(5,324)	
Income before loss on equity method investment	6,741		5,799		23,506		14,101	
Loss on equity method investment	_		(301)		_		(388)	
Net income	\$ 6,741	\$	5,498	\$	23,506	\$	13,713	
Earnings per common share—basic	\$.23	\$.18	\$.80	\$.46	
Earnings per common share—assuming dilution	\$.23	\$.18	\$.78	\$.45	
Weighted average shares outstanding—basic	29,214		29,892	_	29,496	_	29,854	
Weighted average shares outstanding—assuming dilution	29,805		30,390		30,128		30,470	

AMERICAN VANGUARD CORPORATION AND SUBSIDIARIES ANALYSIS OF SALES

(In thousands) (Unaudited)

For the three months ended September 30

	ended September 30,						
		2022	2021		Change		% Change
Net sales:							
U.S. crop	\$	69,115	\$	66,722	\$	2,393	4%
U.S. non-crop		18,936		21,622		(2,686)	-12%
U.S. total		88,051		88,344		(293)	0%
International		64,066		58,954		5,112	9%
Net sales:	\$	152,117	\$	147,298	\$	4,819	3%
Gross profit:		 -			_		
U.S. crop	\$	34,502	\$	30,237	\$	4,265	14%
U.S. non-crop		8,811		8,882		(71)	-1%
U.S. total	· · · · · · · · · · · · · · · · · · ·	43,313		39,119		4,194	11%
International		18,071		17,945		126	1%
Total gross profit:	\$	61,384	\$	57,064	\$	4,320	8%

For the nine months

	ended Sep					
	2022 2021 Change		Change	% Change		
Net sales:						
U.S. crop	\$ 220,503	\$	184,052	\$ 36,451	20%	
U.S. non-crop	 53,648		60,563	(6,915)	-11%	
U.S. total	274,151		244,615	29,536	12%	
International	175,485		153,448	22,037	14%	
Net sales:	\$ 449,636	\$	398,063	\$ 51,573	13%	
Gross profit:	 					
U.S. crop	\$ 104,599	\$	78,313	\$ 26,286	34%	
U.S. non-crop	24,826		28,047	(3,221)	-11%	
U.S. total	 129,425		106,360	23,065	22%	
International	52,931		47,974	4,957	10%	
Total gross profit:	\$ 182,356	\$	154,334	\$ 28,022	18%	

AMERICAN VANGUARD CORPORATION AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands) (Unaudited)

(Unaudited)	_		_			
	Fo	r the Nine N				
	Septem 2022			2021		
Cash flows from operating activities:		2022		2021		
Net income	\$	23,506	\$	13,713		
Adjustments to reconcile net income to net cash used in operating	Ψ.	20,000	Ψ.	10,710		
activities:						
Depreciation and amortization of property, plant and equipment and intangible assets		16,649		17,045		
Amortization of other long-term assets		2,656		2,981		
Loss on disposal of property, plant and equipment		265				
Accretion of discounted liabilities		28		(10)		
Amortization of deferred loan fees		174		294		
Provision for bad debts		597		1,202		
Loan principal and interest forgiveness		_		(672)		
Fair value adjustment to contingent consideration		621		520		
Stock-based compensation		4,396		5,309		
Change in deferred income taxes		(64)		(560)		
Change in fair value of equity investments		857		(103)		
Loss on equity method investment		_		388		
Adjustment to bargain purchase gain on business acquisition		_		(171)		
Net foreign currency adjustments		218		(330)		
Changes in assets and liabilities associated with operations:						
Increase in net receivables		(46,289)		(42,979)		
Increase in inventories		(38,987)		(4,325)		
Increase in prepaid expenses and other assets		(4,272)		(2,194)		
(Increase) decrease in income tax receivable/payable, net		(5,201)		2,031		
Increase in net operating lease liability		10		183		
Increase in accounts payable		14,418		7,769		
Decrease in customer prepayments		(62,831)		(38,272)		
Increase in accrued program costs		45,016		33,982		
Increase in other payables and accrued expenses		2,555		4,025		
Net cash used in operating activities		(45,678)		(174)		
Cash flows from investing activities:						
Capital expenditures		(8,946)		(7,963)		
Proceeds from disposal of property, plant and equipment		46		_		
Acquisition of product line		_		(10,000)		
Intangible assets		(1,078)		(285)		
Investments		_		(183)		
Net cash used in investing activities		(9,978)		(18,431)		
Cash flows from financing activities:	-					
Payments under line of credit agreement		(64,000)		(57,408)		
Borrowings under line of credit agreement		160,000		86,000		
Payment of contingent consideration		_		(250)		
Net receipt from the issuance of common stock under ESPP		837		743		
Net receipt from the exercise of stock options		783		172		
Payment for tax withholding on stock-based compensation awards		(2,020)		(2,915)		
Repurchase of common stock		(33,731)		(4,579)		
Payment of cash dividends		(2,072)		(1,789)		
Net cash provided by financing activities		59,797		19,974		
Net increase in cash and cash equivalents		4,141		1,369		
Effect of exchange rate changes on cash and cash equivalents		382		(574)		
Cash and cash equivalents at beginning of period		16,285		15,923		
Cash and cash equivalents at end of period	\$	20,808	\$	16,718		
•	_		_			

AMERICAN VANGUARD CORPORATION AND SUBSIDIARIES UNAUDITED RECONCILIATION OF NET INCOME TO ADJUSTED EBITDA

	 Three Months Ended September 30,				Nine Months Ended September 30,			
	2022		2021	2022			2021	
Net income, as reported	\$ 6,741	\$	5,498	\$	23,506	\$	13,713	
Provision for income taxes	2,963		1,517		10,187		5,324	
Interest expense, net	1,086		962		2,256		2,921	
Depreciation and amortization	6,562		7,285		19,305		20,026	
Stock compensation	1,560		1,711		4,396		5,309	
Proxy contest activities	_		_		1,785		_	
Adjusted EBITDA ²	\$ 18,912	\$	16,973	\$	61,435	\$	47,293	

-

² Adjusted earnings before interest, taxes, depreciation, amortization, non-cash stock compensation, and proxy contest activities. Adjusted EBITDA is not a financial measure calculated and presented in accordance with U.S. generally accepted accounting principles (GAAP) and should not be considered as an alternative to net income (loss), operating income (loss) or any other financial measures so calculated and presented, nor as an alternative to cash flow from operating activities as a measure of liquidity. We provide these measures because we believe that they provide helpful comparisons to other companies in our industry and peer group. The items excluded from Adjusted EBITDA are detailed in the reconciliation attached to this news release. Other companies (including the Company's competitors) may define Adjusted EBITDA differently.